Literature DB >> 565464

The treatment of idiopathic thrombocytopenia with vinblastine-loaded platelets.

Y S Ahn, J J Byrnes, W J Harrington, M L Cayer, D S Smith, D E Brunskill, L M Pall.   

Abstract

We devised a method to enhance delivery of vinblastine to macrophages, the cells believed to be responsible for platelet destruction in idiopathic thrombocytopenic purpura. Our strategy was based on the ability of platelets to bind vinca alkaloids such as vinblastine. Platelets were incubated with an excess of vinblastine, concentrated and then, after excess alkaloid had been removed, given to 11 patients with idiopathic thrombocytopenia refractory to other treatment (including intravenous injections of vinca alkaloids). Platelet antibodies in the patients' plasma led to ingestion of the vinca-laden platelets by macrophages. There were six complete remissions, three partial remissions and two failures. Side effects in a few patients, reversible but annoying, were minimized as technics were refined. We conclude that in patients with idiopathic thrombocytopenia refractory to all other measures, including the use of vinca alkaloids, platelet-vinca complex may be effective.

Entities:  

Mesh:

Substances:

Year:  1978        PMID: 565464     DOI: 10.1056/NEJM197805182982001

Source DB:  PubMed          Journal:  N Engl J Med        ISSN: 0028-4793            Impact factor:   91.245


  21 in total

1.  Chronic idiopathic thrombocytogenic purpura.

Authors:  G F Pineo
Journal:  Can Fam Physician       Date:  1984-09       Impact factor: 3.275

2.  [Therapy of a refractory idiopathic thrombocytopenic purpura by vinblastine-loaded thrombocytes (author's transl)].

Authors:  U Budde; R Schmidt; J Gerloff; F Etzel
Journal:  Blut       Date:  1979-02-19

3.  Autoimmune blood dyscrasias in five patients with hypogammaglobulinemia: response of neutropenia to vincristine.

Authors:  A D Webster; T A Platts-Mills; G Jannossy; M Morgan; G L Asherson
Journal:  J Clin Immunol       Date:  1981-04       Impact factor: 8.317

4.  Vindesine. A clinical trial with special reference to neurological side effects.

Authors:  R Obrist; U Paravicini; D Hartmann; G A Nagel; J P Obrecht
Journal:  Cancer Chemother Pharmacol       Date:  1979       Impact factor: 3.333

Review 5.  Antibody-mediated targeting in the treatment and diagnosis of cancer: an overview.

Authors:  C H Ford; A G Casson
Journal:  Cancer Chemother Pharmacol       Date:  1986       Impact factor: 3.333

6.  The protein binding of vinblastine in the serum of normal subjects and patients with Hodgkin's disease.

Authors:  W H Steele; D J King; H E Barber; G M Hawksworth; A A Dawson; J C Petrie
Journal:  Eur J Clin Pharmacol       Date:  1983       Impact factor: 2.953

7.  Low-dose vincristine in the treatment of corticosteroid-refractory idiopathic thrombocytopenic purpura (ITP) in non-splenectomized patients.

Authors:  F Cervantes; E Montserrat; C Rozman; C Diumenjo; E Feliu; A Grañena
Journal:  Postgrad Med J       Date:  1980-10       Impact factor: 2.401

Review 8.  The nontreatment of childhood idiopathic thrombocytopenic purpura.

Authors:  G R Buchanan
Journal:  Eur J Pediatr       Date:  1987-03       Impact factor: 3.183

9.  Idiopathic thrombocytopenia, initial illness and long term follow up.

Authors:  R W Walker; W Walker
Journal:  Arch Dis Child       Date:  1984-04       Impact factor: 3.791

10.  Slow infusions of vinblastine in the treatment of adult idiopathic thrombocytopenic purpura: a report on 43 cases.

Authors:  P Fenaux; I Quiquandon; M T Caulier; M Simon; M P Walter; F Bauters
Journal:  Blut       Date:  1990-04
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.